Replies to post #37717 on RespireRx Pharmaceuticals Inc (fka RSPI)

[enemem]

It worries me that you had the same idea. Do you think this would be legal? A CEO of one company sets up another company, sells his company to the new company, and then moves to the new company as CEO. This is sort of like screwing it forward. The fact that Stoll isn't quashing it, and Varney isn't responding gives this thing some credence.
Newman-Tancredi operates out of France, and the only pharma with a stake in corx right now is Servier, which has a bad reputation in france, where they face charges of fraud:
http://www.latribune.fr/entreprises-finance/industrie/chimie-pharmacie/20110926trib000651801/en-attendant-son-proces-servier-rassure-ses-employes-.html

Along with an extensive track-record of hiding dangerous/lethal side effects of their drugs (the attached article translates as "Servier: the shame of french pharma")
http://cpolitic.wordpress.com/2007/11/20/laboratoire-servier-la-honte-de-lindustrie-pharmaceutique-francaise/
the details are pretty hair-raising, particularly a weight-loss drug Isomeride, which caused heart damage.

So Neurolixis may be focusing on delivering corx to Servier, perhaps with Servier's collusion.

[Market_Fest4]

sounds about right.
MF4

[scstocks]

===licenses CORX IP for a pittance===

Not sure, but wouldn't the Univer. have something to say about that?

[DewDiligence]

Here's another take on the issue...and one that holds little promise for existing CORX shareholders: Varney sets up a new corporation and then licenses CORX IP for a pittance. He and his cronies then jump ship to Neurolixis leaving CORX with no tangible value and a new crop of "owners" with the ability to move ampakines forward.

No idea whether such a thing is happening here; however, I’ve seen this maneuver executed in two prior instances involving biotech companies. In both cases, the companies that originally owned the IP ended up filing for bankruptcy.